ICI TALON CONCENTRATE RODENTICIDE

Main information

  • Trade name:
  • ICI TALON CONCENTRATE RODENTICIDE
  • Class:
  • AgChem
  • Medicine domain:
  • Plants
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ICI TALON CONCENTRATE RODENTICIDE
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • INDUSTRIAL AND/OR DOMESTIC PREMISES | IN AND AROUND | PREMISES
  • Therapeutic area:
  • VERTEBRATE POISON
  • Therapeutic indications:
  • MOUSE - MUS SPP. | RAT

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Archived
  • Authorization number:
  • 33899
  • Last update:
  • 09-08-2016

21-1-2019

Ruling by the French administrative court of Lyon: ANSES contests any error of assessment

Ruling by the French administrative court of Lyon: ANSES contests any error of assessment

ANSES has examined the ruling of 15 January 2019 by the French administrative court of Lyon overriding the marketing authorisation decision for Roundup Pro 360. It should be noted that, in order to protect human and environmental health, ANSES is responsible for implementing European regulations on the national level with regard to the marketing authorisation of regulated products (plant protection products, biocides and veterinary medicinal products). It also contributes to improving these regulations b...

France - Agence Nationale du Médicament Vétérinaire

18-1-2019

Updating of summaries of product characteristics due to changed ATC codes for 2019

Updating of summaries of product characteristics due to changed ATC codes for 2019

Marketing authorisation holders of medicinal products authorised under the national procedure, the decentralised procedure as well as the mutual recognition procedure should be aware that some ATC codes have been changed for 2019.

Danish Medicines Agency

16-1-2019

Reimbursement of medicinal cannabis of the pilot programme effective as of 1 January 2019

Reimbursement of medicinal cannabis of the pilot programme effective as of 1 January 2019

On 1 January 2019, a special reimbursement scheme for medicinal cannabis in the four-year pilot programme entered into force. Reimbursement is retroactive for purchases made in 2018.

Danish Medicines Agency

15-1-2019


Committee for Advanced Therapies (CAT): 7-9 November 2018, European Medicines Agency, London, UK, from 07/11/2018 to 08/11/2018

Committee for Advanced Therapies (CAT): 7-9 November 2018, European Medicines Agency, London, UK, from 07/11/2018 to 08/11/2018

Committee for Advanced Therapies (CAT): 7-9 November 2018, European Medicines Agency, London, UK, from 07/11/2018 to 08/11/2018

Europe - EMA - European Medicines Agency

14-1-2019


Concept paper on the revision of the guideline on the evaluation of anticancer medicinal products in man

Concept paper on the revision of the guideline on the evaluation of anticancer medicinal products in man

Concept paper on the revision of the guideline on the evaluation of anticancer medicinal products in man

Europe - EMA - European Medicines Agency

14-1-2019


Draft guideline on the evaluation of medicinal products indicated for treatment of bacterial infections - Revision 3

Draft guideline on the evaluation of medicinal products indicated for treatment of bacterial infections - Revision 3

Draft guideline on the evaluation of medicinal products indicated for treatment of bacterial infections - Revision 3

Europe - EMA - European Medicines Agency

10-1-2019


Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies, European Medicines Agency, London, UK, from 26/11/2018 to 26/11/2018

Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies, European Medicines Agency, London, UK, from 26/11/2018 to 26/11/2018

Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies, European Medicines Agency, London, UK, from 26/11/2018 to 26/11/2018

Europe - EMA - European Medicines Agency

7-1-2019


EU Innovation Network workshop with academia, European Medicines Agency, London, UK, from 16/11/2018 to 16/11/2018

EU Innovation Network workshop with academia, European Medicines Agency, London, UK, from 16/11/2018 to 16/11/2018

EU Innovation Network workshop with academia, European Medicines Agency, London, UK, from 16/11/2018 to 16/11/2018

Europe - EMA - European Medicines Agency

20-12-2018

New report on adverse reactions reported with tramadol for pain relief

New report on adverse reactions reported with tramadol for pain relief

The Danish Medicines Agency has received 830 reports of suspected adverse reactions with tramadol since the medicine was marketed in March 1993. 155 of them describe symptoms of dependence. This follows from a report that has just been published. In 2017, about 265,000 individuals received treatment with tramadol in Denmark.

Danish Medicines Agency

20-12-2018

Workshop on Avian Influenza

Workshop on Avian Influenza

Published on: Wed, 19 Dec 2018 Since September 2017, EFSA has been providing ongoing scientific and technical support to the European Commission and Member States (MSs) in the collection, collation, and analysis of epidemiological data relevant to the monitoring of avian influenza (AI) viruses in Europe and third countries. From 2019 onwards, EFSA will also be responsible for collecting, collating, and analysing the data gathered by MSs via their surveillance programmes in poultry and wild birds. To eff...

Europe - EFSA - European Food Safety Authority EFSA Journal

19-12-2018


Draft guideline for the demonstration of efficacy for veterinary medicinal products containing anticoccidial substances - Revision 1

Draft guideline for the demonstration of efficacy for veterinary medicinal products containing anticoccidial substances - Revision 1

Draft guideline for the demonstration of efficacy for veterinary medicinal products containing anticoccidial substances - Revision 1

Europe - EMA - European Medicines Agency

19-12-2018

Nature's Ultimate recalls Nature's Ultimate - Concentrated Cleaner 1.9L (64 fl. oz)

Nature's Ultimate recalls Nature's Ultimate - Concentrated Cleaner 1.9L (64 fl. oz)

The child-resistant cap on some units of the product may not function as required by the Consumer Chemicals and Containers Regulations, 2001 under the Canada Consumer Product Safety Act.

Health Canada

21-1-2019


Nitrofurantoin, nifurtoinol: List of nationally authorised medicinal products - PSUSA/00002174/201802

Nitrofurantoin, nifurtoinol: List of nationally authorised medicinal products - PSUSA/00002174/201802

Nitrofurantoin, nifurtoinol: List of nationally authorised medicinal products - PSUSA/00002174/201802

Europe - EMA - European Medicines Agency

21-1-2019


Ciprofloxacin (systemic use):  List of nationally authorised medicinal products - PSUSA/00000775/201801

Ciprofloxacin (systemic use): List of nationally authorised medicinal products - PSUSA/00000775/201801

Ciprofloxacin (systemic use): List of nationally authorised medicinal products - PSUSA/00000775/201801

Europe - EMA - European Medicines Agency

18-1-2019


European Medicines Agency practical guidance on the application form for centralised type IA and IB variations for veterinary medicinal products

European Medicines Agency practical guidance on the application form for centralised type IA and IB variations for veterinary medicinal products

European Medicines Agency practical guidance on the application form for centralised type IA and IB variations for veterinary medicinal products

Europe - EMA - European Medicines Agency

18-1-2019


Ivabradine / metoprolol: List of nationally authorised medicinal products - PSUSA/00010381/201804

Ivabradine / metoprolol: List of nationally authorised medicinal products - PSUSA/00010381/201804

Ivabradine / metoprolol: List of nationally authorised medicinal products - PSUSA/00010381/201804

Europe - EMA - European Medicines Agency

17-1-2019

Supplier assessment, approval and qualification for listed and complementary medicines

Supplier assessment, approval and qualification for listed and complementary medicines

Updated to be consistent with PE009-13, the PIC/S Guide to GMP

Therapeutic Goods Administration - Australia

16-1-2019

Erleada (Janssen-Cilag International NV)

Erleada (Janssen-Cilag International NV)

Erleada (Active substance: apalutamide) - New authorisation - Commission Decision (2019)257 of Wed, 16 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4452

Europe -DG Health and Food Safety

16-1-2019

Sampling and testing for listed and complementary medicines

Sampling and testing for listed and complementary medicines

Updated to be consistent with PE009-13, the PIC/S Guide to GMP

Therapeutic Goods Administration - Australia

16-1-2019

Product Quality Reviews (PQRs) for listed and complementary medicines

Product Quality Reviews (PQRs) for listed and complementary medicines

Updated to be consistent with PE009-13, the PIC/S Guide to GMP

Therapeutic Goods Administration - Australia

16-1-2019

Process validation for listed and complementary medicines

Process validation for listed and complementary medicines

Updated to be consistent with PE009-13, the PIC/S Guide to GMP

Therapeutic Goods Administration - Australia

15-1-2019

Ongoing stability testing for listed and complementary medicines

Ongoing stability testing for listed and complementary medicines

Updated to be consistent with PE009-13, the PIC/S Guide to GMP

Therapeutic Goods Administration - Australia

15-1-2019

Macimorelin Aeterna Zentaris (Aterna Zentaris GmbH)

Macimorelin Aeterna Zentaris (Aterna Zentaris GmbH)

Macimorelin Aeterna Zentaris (Active substance: macimorelin) - New authorisation - Commission Decision (2019)203 of Tue, 15 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4660

Europe -DG Health and Food Safety

15-1-2019

Medicinal gases guidance

Medicinal gases guidance

Medicinal gases guidance has been updated to reflect expectations of the new PIC/S guide to GMP PE009-13

Therapeutic Goods Administration - Australia

14-1-2019


Human medicines highlights - January 2019

Human medicines highlights - January 2019

Human medicines highlights - January 2019

Europe - EMA - European Medicines Agency

14-1-2019

Paclitaxel Hetero and associated names

Paclitaxel Hetero and associated names

Paclitaxel Hetero and associated names (Active substance: paclitaxel) - Community Referrals - Art 29 - Commission Decision (2019)205 of Mon, 14 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H//A-29(4)/1466

Europe -DG Health and Food Safety

14-1-2019


Revised guideline aims to strengthen global approach to development of new antibacterial medicines

Revised guideline aims to strengthen global approach to development of new antibacterial medicines

Revised guideline aims to strengthen global approach to development of new antibacterial medicines

Europe - EMA - European Medicines Agency

14-1-2019


Applications for new human medicines under evaluation by the CHMP: January 2019

Applications for new human medicines under evaluation by the CHMP: January 2019

Applications for new human medicines under evaluation by the CHMP: January 2019

Europe - EMA - European Medicines Agency

14-1-2019

Submissions received: Benzocaine: proposed advisory statements for medicines

Submissions received: Benzocaine: proposed advisory statements for medicines

Submissions received on the Benzocaine: proposed advisory statements for medicines have been published

Therapeutic Goods Administration - Australia

14-1-2019

Consultation: Benzocaine: proposed advisory statements for medicines

Consultation: Benzocaine: proposed advisory statements for medicines

The TGA is seeking comments on proposed new required label statements for medicines containing benzocaine. Closing date: 16 October 2018

Therapeutic Goods Administration - Australia

11-1-2019

Syvazul BTV (LABORATORIOS SYVA, S.A.U.)

Syvazul BTV (LABORATORIOS SYVA, S.A.U.)

Syvazul BTV (Active substance: Bluetongue virus vaccine (inactivated) (multistrain: 1-2 strains out of a set of 3)) - New authorisation - Commission Decision (2019)135 of Fri, 11 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/V/C/4611

Europe -DG Health and Food Safety

11-1-2019

Isemid (Ceva SantE Animale)

Isemid (Ceva SantE Animale)

Isemid (Active substance: Torasemide) - New authorisation - Commission Decision (2019)134 of Fri, 11 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/4345

Europe -DG Health and Food Safety

10-1-2019


BCG vaccine (freeze-dried): List of nationally authorised medicinal products - PSUSA/00000304/201803

BCG vaccine (freeze-dried): List of nationally authorised medicinal products - PSUSA/00000304/201803

BCG vaccine (freeze-dried): List of nationally authorised medicinal products - PSUSA/00000304/201803

Europe - EMA - European Medicines Agency

10-1-2019


Lorazepam: List of nationally authorised medicinal products - PSUSA/00001909/201801

Lorazepam: List of nationally authorised medicinal products - PSUSA/00001909/201801

Lorazepam: List of nationally authorised medicinal products - PSUSA/00001909/201801

Europe - EMA - European Medicines Agency

9-1-2019


Guideline on assessment and control of DNA reactive (mutagenic) impurities in veterinary medicinal products

Guideline on assessment and control of DNA reactive (mutagenic) impurities in veterinary medicinal products

Guideline on assessment and control of DNA reactive (mutagenic) impurities in veterinary medicinal products

Europe - EMA - European Medicines Agency

9-1-2019

Silodosin Recordati (Recordati Ireland Ltd)

Silodosin Recordati (Recordati Ireland Ltd)

Silodosin Recordati (Active substance: silodosin) - New authorisation - Commission Decision (2019)73 of Wed, 09 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/4964

Europe -DG Health and Food Safety

7-1-2019


Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized mRNA that will be translated to functional human cystic fibrosis transmembrane conductance regulator protein after cellular uptake

Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized mRNA that will be translated to functional human cystic fibrosis transmembrane conductance regulator protein after cellular uptake

Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized mRNA that will be translated to functional human cystic fibrosis transmembrane conductance regulator protein after cellular uptake

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicines: Allogeneic Epstein-Barr Virus specific cytotoxic T lymphocytes

Scientific recommendation on classification of advanced therapy medicines: Allogeneic Epstein-Barr Virus specific cytotoxic T lymphocytes

Scientific recommendation on classification of advanced therapy medicines: Allogeneic Epstein-Barr Virus specific cytotoxic T lymphocytes

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicines: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Scientific recommendation on classification of advanced therapy medicines: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Scientific recommendation on classification of advanced therapy medicines: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 9 vector encoding the soluble lysosomal enzyme TPP1

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 9 vector encoding the soluble lysosomal enzyme TPP1

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 9 vector encoding the soluble lysosomal enzyme TPP1

Europe - EMA - European Medicines Agency

4-1-2019


Veterinary medicines: highlights of 2018

Veterinary medicines: highlights of 2018

Veterinary medicines: highlights of 2018

Europe - EMA - European Medicines Agency

4-1-2019


Human medicines: highlights of 2018

Human medicines: highlights of 2018

Human medicines: highlights of 2018

Europe - EMA - European Medicines Agency

4-1-2019


Human medicines highlights 2018

Human medicines highlights 2018

Human medicines highlights 2018

Europe - EMA - European Medicines Agency

3-1-2019

South Australian man faces criminal charges for dealing with counterfeit and unapproved medicines

South Australian man faces criminal charges for dealing with counterfeit and unapproved medicines

Dealing countefeit and unapproved medicines is a serious offence as shown in recent TGA prosecution outcome in South Australia

Therapeutic Goods Administration - Australia

3-1-2019

Submissions received and high level summary: Transition to eCTD only for prescription medicines

Submissions received and high level summary: Transition to eCTD only for prescription medicines

The TGA would like to thank respondents who provided submissions in response to the October 2018 public consultation paper

Therapeutic Goods Administration - Australia

20-12-2018

Namuscla (Lupin Europe GmbH)

Namuscla (Lupin Europe GmbH)

Namuscla (Active substance: Mexiletine) - New authorisation - Commission Decision (2018)9133 of Thu, 20 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4584

Europe -DG Health and Food Safety

20-12-2018

Bevespi Aerosphere (AstraZeneca AB)

Bevespi Aerosphere (AstraZeneca AB)

Bevespi Aerosphere (Active substance: glycopyrronium bromide / formoterol) - New authorisation - Commission Decision (2018)9127 of Thu, 20 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4245

Europe -DG Health and Food Safety

19-12-2018


Enalapril: List of nationally authorised medicinal products - PSUSA/00001211/201803

Enalapril: List of nationally authorised medicinal products - PSUSA/00001211/201803

Enalapril: List of nationally authorised medicinal products - PSUSA/00001211/201803

Europe - EMA - European Medicines Agency

19-12-2018


Overview of comments received on 'Guideline on the conduct of bioequivalence studies for veterinary medicinal products' (EMA/CVMP/016/00-Rev.3) - Revision 3

Overview of comments received on 'Guideline on the conduct of bioequivalence studies for veterinary medicinal products' (EMA/CVMP/016/00-Rev.3) - Revision 3

Overview of comments received on 'Guideline on the conduct of bioequivalence studies for veterinary medicinal products' (EMA/CVMP/016/00-Rev.3) - Revision 3

Europe - EMA - European Medicines Agency

19-12-2018


Guideline on the conduct of bioequivalence studies for veterinary medicinal products - Revision 3

Guideline on the conduct of bioequivalence studies for veterinary medicinal products - Revision 3

Guideline on the conduct of bioequivalence studies for veterinary medicinal products - Revision 3

Europe - EMA - European Medicines Agency

19-12-2018

Perlinring and associated names

Perlinring and associated names

Perlinring and associated names (Active substance: etonogestrel/ethinylestradiol) - Community Referrals - Art 29 - Commission Decision (2018)9141 of Wed, 19 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/A-29(4)/1473

Europe -DG Health and Food Safety

19-12-2018


European Medicines Agency closed 21 December 2018 to 2 January 2019

European Medicines Agency closed 21 December 2018 to 2 January 2019

European Medicines Agency closed 21 December 2018 to 2 January 2019

Europe - EMA - European Medicines Agency

18-12-2018


Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00010390/201801

Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00010390/201801

Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00010390/201801

Europe - EMA - European Medicines Agency

18-12-2018


Mycophenolate mofetil, mycophenolic acid : List of nationally authorised medicinal products - PSUSA/00010550/201805

Mycophenolate mofetil, mycophenolic acid : List of nationally authorised medicinal products - PSUSA/00010550/201805

Mycophenolate mofetil, mycophenolic acid : List of nationally authorised medicinal products - PSUSA/00010550/201805

Europe - EMA - European Medicines Agency

18-12-2018


Human medicines European public assessment report (EPAR): Dengvaxia, dengue tetravalent vaccine (live, attenuated), Dengue, Date of authorisation: 12/12/2018, Status: Authorised

Human medicines European public assessment report (EPAR): Dengvaxia, dengue tetravalent vaccine (live, attenuated), Dengue, Date of authorisation: 12/12/2018, Status: Authorised

Human medicines European public assessment report (EPAR): Dengvaxia, dengue tetravalent vaccine (live, attenuated), Dengue, Date of authorisation: 12/12/2018, Status: Authorised

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells isolated from autologous bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells isolated from autologous bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells isolated from autologous bone marrow

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous melanocytes

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous melanocytes

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous melanocytes

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous muscle-derived stem cells

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous muscle-derived stem cells

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous muscle-derived stem cells

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Human autologous keratinocytes

Scientific recommendation on classification of advanced therapy medicinal products: Human autologous keratinocytes

Scientific recommendation on classification of advanced therapy medicinal products: Human autologous keratinocytes

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Viable human autologous skin fibroblasts

Scientific recommendation on classification of advanced therapy medicinal products: Viable human autologous skin fibroblasts

Scientific recommendation on classification of advanced therapy medicinal products: Viable human autologous skin fibroblasts

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous chondrocytes

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous chondrocytes

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous chondrocytes

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured adipose derived mesenchymal stem cells

Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured adipose derived mesenchymal stem cells

Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured adipose derived mesenchymal stem cells

Europe - EMA - European Medicines Agency